-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▾ Click to listen to the content of this issue ▾ A study published online by "Nature", Evolution of Antibody Immunity to SARS-CoV-2, shows that the immunity after infection with the new coronavirus (SARS-CoV-2) may be maintained for at least 6 months.
This study analyzed 87 people who had been infected with SARS-CoV-2 and found that their specific memory B cell levels did not change throughout the study period-memory B cells are immune cells that remain in the body after infection, and SARS- CoV-2 can rapidly multiply and produce antibodies when it is reinfected.
The results of the study indicate that when individuals who have been infected with SARS-CoV-2 are exposed to the virus again, they may respond quickly and effectively.
The human immune system produces antibodies during infection, and these antibodies can specifically neutralize the infectious agent.
Human antibodies against SARS-CoV-2 have been shown to prevent infection in animal models.
The level of these antibodies may decrease over time, but as the name suggests, memory B cells can "remember" the infectious agent and induce the immune system to produce the same antibodies during reinfection.
Michel Nussenzweig of Rockefeller University in New York and colleagues evaluated the conditions of 87 COVID-19 confirmed patients 1.
3 months and 6.
2 months after being infected with SARS-CoV-2.
They found that although the activity of neutralizing antibodies decreased over time, the number of memory B cells did not change.
In addition, the authors proved that the antibodies produced by these cells are stronger than the original antibodies and are more resistant to mutations in the spike protein that helps the virus enter the cell.
These observations indicate that memory B cells have the ability to evolve in the presence of a small amount of persistent viral antigens (small viral proteins that can be recognized by the immune system).
The authors concluded that the continued existence and evolution of memory B cells indicate that when SARS-CoV-2 reinfection occurs, the human body may quickly produce powerful virus-neutralizing antibodies.
©Nature Nature | doi: 10.
1038/s41586-021-03207-w
This study analyzed 87 people who had been infected with SARS-CoV-2 and found that their specific memory B cell levels did not change throughout the study period-memory B cells are immune cells that remain in the body after infection, and SARS- CoV-2 can rapidly multiply and produce antibodies when it is reinfected.
The results of the study indicate that when individuals who have been infected with SARS-CoV-2 are exposed to the virus again, they may respond quickly and effectively.
The human immune system produces antibodies during infection, and these antibodies can specifically neutralize the infectious agent.
Human antibodies against SARS-CoV-2 have been shown to prevent infection in animal models.
The level of these antibodies may decrease over time, but as the name suggests, memory B cells can "remember" the infectious agent and induce the immune system to produce the same antibodies during reinfection.
Michel Nussenzweig of Rockefeller University in New York and colleagues evaluated the conditions of 87 COVID-19 confirmed patients 1.
3 months and 6.
2 months after being infected with SARS-CoV-2.
They found that although the activity of neutralizing antibodies decreased over time, the number of memory B cells did not change.
In addition, the authors proved that the antibodies produced by these cells are stronger than the original antibodies and are more resistant to mutations in the spike protein that helps the virus enter the cell.
These observations indicate that memory B cells have the ability to evolve in the presence of a small amount of persistent viral antigens (small viral proteins that can be recognized by the immune system).
The authors concluded that the continued existence and evolution of memory B cells indicate that when SARS-CoV-2 reinfection occurs, the human body may quickly produce powerful virus-neutralizing antibodies.
©Nature Nature | doi: 10.
1038/s41586-021-03207-w
